<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019e2327-b8d0-7b47-bc69-5c2fbcbee005,g:96a19e7c-0d95-4745-bfb2-e02eb0513344-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhvn-20260630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e2327-ba40-7dec-ab81-550778de094f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e2327-ba40-7e58-91d7-cb391b9baaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e2327-ba40-7dec-ab81-550778de094f" xlink:to="loc_us-gaap_Liabilities_019e2327-ba40-7e58-91d7-cb391b9baaeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019e2327-ba40-7ca0-82c6-d26d87cdad63" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e2327-ba40-7dec-ab81-550778de094f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019e2327-ba40-7ca0-82c6-d26d87cdad63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e2327-ba40-7ec9-bca1-a5276518243d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019e2327-ba40-7dec-ab81-550778de094f" xlink:to="loc_us-gaap_StockholdersEquity_019e2327-ba40-7ec9-bca1-a5276518243d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019e2327-ba40-7bfa-9dc0-8165773b4688" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e2327-ba40-7c47-b163-f1e02fa2e261" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e2327-ba40-7bfa-9dc0-8165773b4688" xlink:to="loc_us-gaap_AssetsCurrent_019e2327-ba40-7c47-b163-f1e02fa2e261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_019e2327-ba40-70cd-946e-e8cd1389f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e2327-ba40-7bfa-9dc0-8165773b4688" xlink:to="loc_us-gaap_Goodwill_019e2327-ba40-70cd-946e-e8cd1389f6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019e2327-ba40-7e3c-9f11-5dd935276271" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e2327-ba40-7bfa-9dc0-8165773b4688" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019e2327-ba40-7e3c-9f11-5dd935276271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e2327-ba40-7c54-8f70-688d7954c567" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e2327-ba40-7bfa-9dc0-8165773b4688" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_019e2327-ba40-7c54-8f70-688d7954c567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e2327-ba40-73ca-a224-401f4c5eb439" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019e2327-ba40-7bfa-9dc0-8165773b4688" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019e2327-ba40-73ca-a224-401f4c5eb439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019e2327-ba40-7fcb-b45f-c63b6ffd552e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_019e2327-ba40-7013-b419-45b29316a4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e2327-ba40-7fcb-b45f-c63b6ffd552e" xlink:to="loc_us-gaap_PreferredStockValue_019e2327-ba40-7013-b419-45b29316a4ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e2327-ba40-7992-932e-72ae5f20e800" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e2327-ba40-7fcb-b45f-c63b6ffd552e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019e2327-ba40-7992-932e-72ae5f20e800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_019e2327-ba40-7d02-b98b-45aa8550890e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e2327-ba40-7fcb-b45f-c63b6ffd552e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_019e2327-ba40-7d02-b98b-45aa8550890e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019e2327-ba40-7c6c-b303-bfd6ba622ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e2327-ba40-7fcb-b45f-c63b6ffd552e" xlink:to="loc_us-gaap_CommonStockValue_019e2327-ba40-7c6c-b303-bfd6ba622ef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e2327-ba40-73b2-9f2d-cb228a04ccc3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019e2327-ba40-7fcb-b45f-c63b6ffd552e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019e2327-ba40-73b2-9f2d-cb228a04ccc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019e2327-ba40-795b-aa55-b50eefd1710b" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_019e2327-ba40-706f-ad0c-ceff960e42c8" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e2327-ba40-795b-aa55-b50eefd1710b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_019e2327-ba40-706f-ad0c-ceff960e42c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_019e2327-ba40-7689-a5ea-08583808f7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e2327-ba40-795b-aa55-b50eefd1710b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_019e2327-ba40-7689-a5ea-08583808f7f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e2327-ba40-7fa2-947d-b4aab4e8d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e2327-ba40-795b-aa55-b50eefd1710b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e2327-ba40-7fa2-947d-b4aab4e8d28d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_019e2327-ba40-7bae-a838-f86f7932e8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019e2327-ba40-795b-aa55-b50eefd1710b" xlink:to="loc_us-gaap_OtherAssetsCurrent_019e2327-ba40-7bae-a838-f86f7932e8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_019e2327-ba40-7645-89a3-094499a1aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e2327-ba40-7db8-b4e1-530cf1f84efc" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e2327-ba40-7645-89a3-094499a1aca3" xlink:to="loc_us-gaap_LiabilitiesCurrent_019e2327-ba40-7db8-b4e1-530cf1f84efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019e2327-ba40-7425-a729-046db97aadfd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e2327-ba40-7645-89a3-094499a1aca3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_019e2327-ba40-7425-a729-046db97aadfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019e2327-ba40-7000-a759-914e2d816f83" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e2327-ba40-7645-89a3-094499a1aca3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019e2327-ba40-7000-a759-914e2d816f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_019e2327-ba40-785b-baff-86d0501c32d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_019e2327-ba40-7645-89a3-094499a1aca3" xlink:to="loc_us-gaap_LongTermNotesPayable_019e2327-ba40-785b-baff-86d0501c32d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019e2327-ba40-7a6d-9f66-54f852d519aa" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019e2327-ba40-75a7-96cd-458ab7ba61d1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e2327-ba40-7a6d-9f66-54f852d519aa" xlink:to="loc_us-gaap_AccountsPayableCurrent_019e2327-ba40-75a7-96cd-458ab7ba61d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-ba40-7634-9d99-5bf3722c702f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019e2327-ba40-7a6d-9f66-54f852d519aa" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-ba40-7634-9d99-5bf3722c702f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhvn-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e2327-ba40-7257-978b-9e145272fee0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e2327-ba40-7217-8e7d-98429e602096" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e2327-ba40-7257-978b-9e145272fee0" xlink:to="loc_us-gaap_OperatingIncomeLoss_019e2327-ba40-7217-8e7d-98429e602096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019e2327-ba40-7040-a840-1d2046260f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e2327-ba40-7257-978b-9e145272fee0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019e2327-ba40-7040-a840-1d2046260f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e2327-ba40-73d5-8c71-2ad49d9d810c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e2327-ba40-71a5-a112-ea3342a1e3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e2327-ba40-73d5-8c71-2ad49d9d810c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019e2327-ba40-71a5-a112-ea3342a1e3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019e2327-ba40-7820-b90d-c5a49c8940ae" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019e2327-ba40-73d5-8c71-2ad49d9d810c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019e2327-ba40-7820-b90d-c5a49c8940ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e2327-ba40-7724-a891-8ed0d444b418" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e2327-ba40-7d9b-95e3-0eb13d069205" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e2327-ba40-7724-a891-8ed0d444b418" xlink:to="loc_us-gaap_NetIncomeLoss_019e2327-ba40-7d9b-95e3-0eb13d069205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019e2327-ba40-7948-9263-b41b6fcf1268" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019e2327-ba40-7724-a891-8ed0d444b418" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019e2327-ba40-7948-9263-b41b6fcf1268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e2327-ba40-7a6a-8809-ceacdb3a9cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019e2327-ba40-7209-a03b-229cb49773f9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e2327-ba40-7a6a-8809-ceacdb3a9cdb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019e2327-ba40-7209-a03b-229cb49773f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019e2327-ba40-731c-86cc-37fa043cf704" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_019e2327-ba40-7a6a-8809-ceacdb3a9cdb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019e2327-ba40-731c-86cc-37fa043cf704" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019e2327-ba40-791c-81b4-779aa48db2af" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_019e2327-ba40-7c7c-8d19-c7a2761aef27" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019e2327-ba40-791c-81b4-779aa48db2af" xlink:to="loc_us-gaap_CostsAndExpenses_019e2327-ba40-7c7c-8d19-c7a2761aef27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhvn-20260630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019e2327-ba40-7753-af05-10fae4d87842" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_us-gaap_ShareBasedCompensation_019e2327-ba40-7753-af05-10fae4d87842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_019e2327-ba40-77d4-874c-68e253890be0" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_019e2327-ba40-77d4-874c-68e253890be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_019e2327-ba40-7c12-99dc-a91ccd03a73f" xlink:href="bhvn-20260630.xsd#bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_bhvn_ProceedsFromIssuanceOfCommonStockForLicenseAgreements_019e2327-ba40-7c12-99dc-a91ccd03a73f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019e2327-ba40-7b2c-a6ed-3fdf77c38429" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019e2327-ba40-7b2c-a6ed-3fdf77c38429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019e2327-ba40-7247-8e81-314654d1372d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019e2327-ba40-7247-8e81-314654d1372d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_ChangeInFairValueOfDerivativeLiabilities_019e2327-ba40-7925-9333-a6b3f27ae725" xlink:href="bhvn-20260630.xsd#bhvn_ChangeInFairValueOfDerivativeLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_bhvn_ChangeInFairValueOfDerivativeLiabilities_019e2327-ba40-7925-9333-a6b3f27ae725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019e2327-ba40-7512-ad3b-e8b7ff3d8b89" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_us-gaap_NetIncomeLoss_019e2327-ba40-7512-ad3b-e8b7ff3d8b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019e2327-ba40-751b-a3be-0f093ea2f37e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_019e2327-ba40-751b-a3be-0f093ea2f37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e2327-ba40-7536-bf0a-57f1101cf962" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_019e2327-ba40-7536-bf0a-57f1101cf962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_FairValueAdjustmentOfNotesPayable_019e2327-ba40-7a16-8f8c-d852d73c79da" xlink:href="bhvn-20260630.xsd#bhvn_FairValueAdjustmentOfNotesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-77c1-b6eb-30f9e7eae1ed" xlink:to="loc_bhvn_FairValueAdjustmentOfNotesPayable_019e2327-ba40-7a16-8f8c-d852d73c79da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e2327-ba40-76da-a9ff-1b92f16e9c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019e2327-ba40-7ad7-b1f5-ef6befb6c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e2327-ba40-76da-a9ff-1b92f16e9c1f" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_019e2327-ba40-7ad7-b1f5-ef6befb6c7c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019e2327-ba40-72c0-b7cf-6fe6e0d77be1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e2327-ba40-76da-a9ff-1b92f16e9c1f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_019e2327-ba40-72c0-b7cf-6fe6e0d77be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019e2327-ba40-787e-a8f9-73ef227cce56" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e2327-ba40-76da-a9ff-1b92f16e9c1f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019e2327-ba40-787e-a8f9-73ef227cce56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019e9569-f150-78bc-adc2-bcbc5cd3b67e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e2327-ba40-76da-a9ff-1b92f16e9c1f" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_019e9569-f150-78bc-adc2-bcbc5cd3b67e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e2327-ba40-74ec-9169-33f9537426a1" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-7dd3-86d1-c013c0d308ca" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e2327-ba40-74ec-9169-33f9537426a1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019e2327-ba40-7dd3-86d1-c013c0d308ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e2327-ba40-7ba9-afb7-f6655b9371b9" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e2327-ba40-74ec-9169-33f9537426a1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019e2327-ba40-7ba9-afb7-f6655b9371b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-7c15-b835-a2265e51c452" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e2327-ba40-74ec-9169-33f9537426a1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-7c15-b835-a2265e51c452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e2327-ba40-74ca-aa27-e6daaeb5e780" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019e2327-ba40-74ec-9169-33f9537426a1" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e2327-ba40-74ca-aa27-e6daaeb5e780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-74b8-933c-2e3369def2db" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_019e2327-ba40-7dcd-ac13-73953cd3cc59" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-74b8-933c-2e3369def2db" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_019e2327-ba40-7dcd-ac13-73953cd3cc59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019e2327-ba40-7130-a47b-f27bb51b8b13" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-74b8-933c-2e3369def2db" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019e2327-ba40-7130-a47b-f27bb51b8b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e2327-ba40-7c20-b374-8d8e11183bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-74b8-933c-2e3369def2db" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_019e2327-ba40-7c20-b374-8d8e11183bbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019e956a-0afc-7264-8add-4bbab27c8270" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-74b8-933c-2e3369def2db" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_019e956a-0afc-7264-8add-4bbab27c8270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019e956a-0afc-7168-8a06-1820212e9c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019e2327-ba40-74b8-933c-2e3369def2db" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_019e956a-0afc-7168-8a06-1820212e9c3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="bhvn-20260630.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e2327-ba40-7914-8525-9c3f579bdce3" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e2327-ba40-7c44-b1b2-9b8ec81762cd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e2327-ba40-7914-8525-9c3f579bdce3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019e2327-ba40-7c44-b1b2-9b8ec81762cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_019e2327-ba40-74f1-ba6c-89d24089fe9a" xlink:href="bhvn-20260630.xsd#bhvn_RestrictedCashIncludedInOtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e2327-ba40-7914-8525-9c3f579bdce3" xlink:to="loc_bhvn_RestrictedCashIncludedInOtherCurrentAssets_019e2327-ba40-74f1-ba6c-89d24089fe9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_019e2327-ba40-7045-b453-033b82defa79" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_019e2327-ba40-7914-8525-9c3f579bdce3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_019e2327-ba40-7045-b453-033b82defa79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="simple" xlink:href="bhvn-20260630.xsd#MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesAmortizedCostandFairValueofDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019e2327-bb05-7ebf-b14e-07b2743e46fd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e2327-bb05-76d7-bcea-17b97844a8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019e2327-bb05-7ebf-b14e-07b2743e46fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019e2327-bb05-76d7-bcea-17b97844a8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e2327-bb05-710f-800a-f1805e255869" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019e2327-bb05-7ebf-b14e-07b2743e46fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019e2327-bb05-710f-800a-f1805e255869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e2327-bb05-7625-be5c-feb85463c49d" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_019e2327-bb05-7ebf-b14e-07b2743e46fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019e2327-bb05-7625-be5c-feb85463c49d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="simple" xlink:href="bhvn-20260630.xsd#MarketableSecuritiesNetInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/MarketableSecuritiesNetInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_019e2327-bb05-7da3-b877-14cd37e23168" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_019e2327-bb05-7878-ba5f-80cf4dee29f5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeDebtSecuritiesOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_019e2327-bb05-7da3-b877-14cd37e23168" xlink:to="loc_us-gaap_InterestIncomeDebtSecuritiesOperating_019e2327-bb05-7878-ba5f-80cf4dee29f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_019e2327-bb05-74fb-bde2-32ca028c51ab" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend_019e2327-bb05-7da3-b877-14cd37e23168" xlink:to="loc_us-gaap_InterestIncomeOther_019e2327-bb05-74fb-bde2-32ca028c51ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_019e2327-bb05-75ba-9ec9-65b8a3c2cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_019e2327-bb05-7cd8-8818-d587179ed0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_019e2327-bb05-75ba-9ec9-65b8a3c2cdf7" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_019e2327-bb05-7cd8-8818-d587179ed0ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInvestmentExpense_019e2327-bb05-7c62-959b-e2234afe5a95" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InvestmentIncomeNet_019e2327-bb05-75ba-9ec9-65b8a3c2cdf7" xlink:to="loc_us-gaap_InvestmentIncomeInvestmentExpense_019e2327-bb05-7c62-959b-e2234afe5a95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="bhvn-20260630.xsd#FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/FairValueofFinancialAssetsandLiabilitiesFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019e2327-bb05-7ca7-b506-07244adc9129" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_019e2327-bb05-7766-bdd0-8cfcc4f3658e" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_019e2327-bb05-7ca7-b506-07244adc9129" xlink:to="loc_us-gaap_DebtInstrumentFairValue_019e2327-bb05-7766-bdd0-8cfcc4f3658e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019e2327-bb05-718b-be09-c572ce8c0e90" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_019e2327-bb05-78e2-939a-f181ce5982b7" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019e2327-bb05-718b-be09-c572ce8c0e90" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_019e2327-bb05-78e2-939a-f181ce5982b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e2327-bb05-7c51-9026-0801a620f1be" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019e2327-bb05-718b-be09-c572ce8c0e90" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019e2327-bb05-7c51-9026-0801a620f1be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_019e2327-bb05-7cde-add0-f89b8e9d80b5" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019e2327-bb05-718b-be09-c572ce8c0e90" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_019e2327-bb05-7cde-add0-f89b8e9d80b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_OtherCurrentAssetsFairValueDisclosure_019e2327-bb05-716a-a8fc-0dd31618005c" xlink:href="bhvn-20260630.xsd#bhvn_OtherCurrentAssetsFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019e2327-bb05-718b-be09-c572ce8c0e90" xlink:to="loc_bhvn_OtherCurrentAssetsFairValueDisclosure_019e2327-bb05-716a-a8fc-0dd31618005c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="bhvn-20260630.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019e2327-bb05-7c0b-abe3-0633a436ee76" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_019e2327-bb05-7e4b-a070-785a7a760879" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019e2327-bb05-7c0b-abe3-0633a436ee76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_019e2327-bb05-7e4b-a070-785a7a760879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e2327-bb05-7eb5-a5a0-8a083044cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_019e2327-bb05-7c0b-abe3-0633a436ee76" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_019e2327-bb05-7eb5-a5a0-8a083044cf9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="bhvn-20260630.xsd#BalanceSheetComponentsOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019e2327-bb05-7cac-92b8-df55816326cb" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_019e2327-bb05-7706-9aaf-3fe9ea0ca7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_019e2327-bb05-7cac-92b8-df55816326cb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_019e2327-bb05-7706-9aaf-3fe9ea0ca7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_019e2327-bb05-7322-b103-2519da96f684" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_019e2327-bb05-7cac-92b8-df55816326cb" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_019e2327-bb05-7322-b103-2519da96f684" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhvn-20260630.xsd#BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biohavenpharma.com/role/BalanceSheetComponentsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-bb05-7709-b6e1-883373956272" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019e2327-bb05-7a8b-a458-da54524e64ce" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-bb05-7709-b6e1-883373956272" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019e2327-bb05-7a8b-a458-da54524e64ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedClinicalTrialCostsCurrent_019e2327-bb05-78e8-894b-dfa9753480ea" xlink:href="bhvn-20260630.xsd#bhvn_AccruedClinicalTrialCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-bb05-7709-b6e1-883373956272" xlink:to="loc_bhvn_AccruedClinicalTrialCostsCurrent_019e2327-bb05-78e8-894b-dfa9753480ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019e2327-bb05-7d95-bebe-7136c55c5047" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-bb05-7709-b6e1-883373956272" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019e2327-bb05-7d95-bebe-7136c55c5047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedConsiderationTrueUpLiability_019e2327-bb05-7333-966f-a50d4bc94b36" xlink:href="bhvn-20260630.xsd#bhvn_AccruedConsiderationTrueUpLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-bb05-7709-b6e1-883373956272" xlink:to="loc_bhvn_AccruedConsiderationTrueUpLiability_019e2327-bb05-7333-966f-a50d4bc94b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e2327-bb05-7322-9ec8-8cbd85b00399" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-bb05-7709-b6e1-883373956272" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_019e2327-bb05-7322-9ec8-8cbd85b00399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhvn_AccruedDevelopmentMilestonePayableCurrent_019f5b28-3672-74b1-86d1-43b86cd58823" xlink:href="bhvn-20260630.xsd#bhvn_AccruedDevelopmentMilestonePayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_019e2327-bb05-7709-b6e1-883373956272" xlink:to="loc_bhvn_AccruedDevelopmentMilestonePayableCurrent_019f5b28-3672-74b1-86d1-43b86cd58823" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
